International Patent: ENGINEERED CELL THERAPY WITH SECRETED ANTIBODIES TARGETING LRRK2

GENEVA, Aug. 21 -- KENAI THERAPEUTICS, INC. filed a patent application (US2026/014781) for “ENGINEERED CELL THERAPY WITH SECRETED ANTIBODIES TARGETING LRRK2”. With publication no. WO/2026/173911, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C12N 15/90

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....